EMA (EU)
GUIDANCE FINAL
Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking
Published: 5/29/2026Detected: 5/29/2026
Summary preview
Updates the EMA CHMP guideline approach for nicotine dependency studies by proposing to widen scope beyond tobacco smoking to include dependence on smoke-free nicotine products (e.g., nicotine inhalation like…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountpsychiatry
respiratory
clinical
safety
labeling
quality
manufacturing
#smoking cessation
#nicotine dependence
#confirmatory trials
#study design
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026